AbCellera Biologics Inc.
2.78
-0.22 (-7.33%)
At close: Jan 14, 2025, 3:59 PM
2.77
-0.36%
Pre-market Jan 15, 2025, 05:17 AM EST
undefined%
Bid 2.77
Market Cap 821.12M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.61
PE Ratio (ttm) -4.56
Forward PE n/a
Analyst Buy
Ask 2.95
Volume 5,440,180
Avg. Volume (20D) 2,619,924
Open 3.04
Previous Close 3.00
Day's Range 2.75 - 3.06
52-Week Range 2.33 - 5.62
Beta undefined

About ABCL

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 586
Stock Exchange NASDAQ
Ticker Symbol ABCL

Analyst Forecast

According to 3 analyst ratings, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 187.77% from the latest price.

Buy 66.67%
Hold 33.33%
Sell 0.00%
Stock Forecasts

Next Earnings Release

AbCellera Biologics Inc. is scheduled to release its earnings on Feb 18, 2025, during market hours.
Analysts project revenue of $7.58M, reflecting a -17.42% YoY shrinking and earnings per share of -0.15, making a -6.25% decrease YoY.
10 months ago · Source
-9.42%
AbCellera Biologics shares are trading lower after... Unlock content with Pro Subscription